Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

SAN DIEGO, April 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a
biopharmaceutical company developing therapeutic candidates for the treatment
of immune and metabolic diseases, today announced the appointment of Mary
Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a
ClassI director with a term of office expiring and to be renewed at the 2014
annual meeting of stockholders.Dr. Hedley will also serve as a member of the
Board's Nominating and Corporate Governance Committee.

Dr. Hedley has served as president of Tesaro, Inc. and as a member of its
Board of Directors since co-founding Tesaro in March 2010. From July 2009 to
February 2010, Dr.Hedley served as executive vice president of operations and
chief scientific officer of Abraxis BioScience, Inc., a biotechnology company.
Dr. Hedley served as executive vice president of Eisai Corporation of North
America from January 2008 until July 2009, following Eisai Co. Ltd.'s
acquisition of MGI Pharma, Inc. in January 2008. Dr. Hedley served in various
positions at MGI Pharma from 2004 through its acquisition in January 2008,
most recently as executive vice president and chief scientific officer. Prior
to that, Dr. Hedley co-founded and served as the president and chief executive
officer of Zycos, Inc., a biotechnology company, which was acquired by MGI
Pharma in 2004. Prior to co-founding Zycos, Dr. Hedley completed two
consecutive postdoctoral fellowships at Harvard University and earned a B.S.
in microbiology from Purdue University and a Ph.D. in Immunology from the
University of Texas, Southwestern Medical Center. She also currently sits on
the board of Youville Place.

Bill Rastetter, Chairman of the board of directors of Receptos, said, "We are
pleased to welcome Mary Lynne to the Receptos Board of Directors. Her
operating and management experience in the life sciences industry, as well as
her deep scientific background, provide unique qualifications and skills which
we believe will be a valuable asset to Receptos and we look forward to working
with her."

AboutReceptos

Receptos is a biopharmaceutical company developing therapeutic candidates for
the treatment of immune and metabolic diseases. The Company's lead program,
RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule
modulator candidate for immune indications, including relapsing multiple
sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also
developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE).
Receptos has established expertise in high resolution protein crystal
structure determination, biology and drug discovery for G-protein-coupled
receptors (GPCRs).

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@receptos.com
 
Press spacebar to pause and continue. Press esc to stop.